Michael <span>J.</span> Schell
Researcher

Michael J. Schell

Academic Rank: Senior Member

Overview

Statistical examination is critical to glean true biological differences from technological artifacts, providing patients the best personalized treatment.

Discipline

    • Biostatistics and Bioinformatics
    • Melanoma Research Center of Excellence
    • Lung Cancer Center of Excellence
    • Chemical Biology and Molecular Medicine Program
    • Cancer Chemoprevention Research Interest Group

Education & Training

    • Florida State University, PhD - Statistics
    • Florida State University, MS - Statistics
Research

Dr. Schell has led the development of a statistical method to analyze AQUA (Automated Quantitative Analysis)-generated tissue microarray (TMA) data. The method is a 7-step procedure which works quite well for identifying and resolving technical problems when two highly correlated variables are available.  This method provides a practical and efficient way of identifying an appropriate transformation (square-root, quarter-root or log), if needed, of AQUA scores that can be used to satisfy the normality assumption required by most of statistical procedures.  This methodology identifies and adjusts for possible row or column spatial bias effects in a 20 x 17 rectangular plate used in the AQUA machine, which arise due to technical processing effects. The method facilitates the identification of possible outliers or leverage data points in the data due to, for instance, air bubbles. Dr. Schell is a member of the Cancer Biomarkers Study Section.  He is also the statistician for a large integral-biomarker phase III multi-center clinical trial in lung cancer.

Publications

  • Leone A, Diorio G, Sexton W, Schell M, Alexandrow M, Fahey JW, Kumar NB. Sulforaphane for the chemoprevention of bladder cancer: molecular mechanism targeted approach. Oncotarget. 2017 May;8(21):35412-35424. Pubmedid: 28423681. Pmcid: PMC5471065.
  • Li J, Smalley I, Schell MJ, Smalley KSM, Chen YA. SinCHet: a MATLAB toolbox for single cell heterogeneity analysis in cancer. Bioinformatics. 2017 May. Pubmedid: 28472395.
  • Han G, Schell MJ, Zhang H, Zelterman D, Pusztai L, Adelson K, Hatzis C. Testing violations of the exponential assumption in cancer clinical trials with survival endpoints. Biometrics. 2017 Jun;73(2):687-695. Pubmedid: 27669414.
  • Kumar NB, Patel R, Pow-Sang J, Spiess PE, Salup R, Williams CR, Schell MJ. Long-term supplementation of decaffeinated green tea extract does not modify body weight or abdominal obesity in a randomized trial of men at high risk for prostate cancer. Oncotarget. 2017 Jun. Pubmedid: 28678746.
  • Scott JG, Berglund A, Schell MJ, Mihaylov I, Fulp WJ, Yue B, Welsh E, Caudell JJ, Ahmed K, Strom TS, Mellon E, Venkat P, Johnstone P, Foekens J, Lee J, Moros E, Dalton WS, Eschrich SA, McLeod H, Harrison LB, Torres-Roca JF. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. Lancet Oncol. 2017 Feb;18(2):202-211. Pubmedid: 27993569.
  • Perez LE, Fernandez H, Ayala E, Beato F, Neuger A, Pidala J, Schell MJ, Anasetti C. Visilizumab with tacrolimus and methotrexate for GvHD prevention after allogeneic hematopoietic cell transplantation from mismatched unrelated donors. Bone Marrow Transplant. 2017 Apr;52(4):627-629. Pubmedid: 27991896. Pmcid: PMC5382111.
  • Kumar NB, Pow-Sang J, Spiess PE, Park J, Salup R, Williams CR, Parnes H, Schell MJ. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins. Oncotarget. 2016 Oct;7(43):70794-70802. Pubmedid: 28053292. Pmcid: PMC5340117.
  • Omolo B, Yang M, Lo FY, Schell MJ, Austin S, Howard K, Madan A, Yeatman TJ. Adaptation of a RAS pathway activation signature from FF to FFPE tissues in colorectal cancer. BMC Med Genomics. 2016 Oct;9(1):65. Pubmedid: 27756306. Pmcid: PMC5069826.
  • Scott JG, Torres-Roca JF, Harrison LB, Berglund AE, Schell M, Mihaylov IB, Fulp WJ, Yue B, Welsh EA, Caudell JJ, Ahmed KA, Strom T, Mellon EA, Venkat PS, Johnstone PA, Moros EG, Lee J, Foekens J, Dalton WS, Eschrich SA, McLeod HL. A Genomic Framework for Precision Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):S215-S216. Pubmedid: 27675815.
  • Chiappori AA, Otterson GA, Dowlati A, Traynor AM, Horn L, Owonikoko TK, Ross HJ, Hann CL, Abu Hejleh T, Nieva J, Zhao X, Schell M, Sullivan DM. A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer. Oncologist. 2016 Oct;21(10):1163-1164. Pubmedid: 27694157. Pmcid: PMC5061534.
  • Schell MJ, Yang M, Teer JK, Lo FY, Madan A, Coppola D, Monteiro AN, Nebozhyn MV, Yue B, Loboda A, Bien-Willner GA, Greenawalt DM, Yeatman TJ. A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC. Nat Commun. 2016 Jun;7:11743. Pubmedid: 27302369. Pmcid: PMC4912618.
  • Schell MJ, Yang M, Missiaglia E, Delorenzi M, Soneson C, Yue B, Nebozhyn M, Loboda A, Bloom G, Yeatman TJ. A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome. Clin Cancer Res. 2016 Feb;22(3):734-745. Pubmedid: 26446941. Pmcid: PMC4802496.
  • Weber J, Gibney G, Kudchadkar RR, Yu B, Cheng P, Martinez AJ, Kroeger J, Richards A, McCormick L, Moberg V, Cronin H, Zhao X, Schell M, Chen YA. Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab. Cancer Immunol Res. 2016 Apr;4(4):345-353. Pubmedid: 26873574. Pmcid: PMC4818672.
  • Smith FO, Yue B, Marzban SS, Walls BL, Carr M, Jackson RS, Puleo CA, Padhya T, Cruse CW, Gonzalez RJ, Sarnaik AA, Schell MJ, DeConti RC, Messina JL, Sondak VK, Zager JS. Both tumor depth and diameter are predictive of sentinel lymph node status and survival in Merkel cell carcinoma. Cancer. 2015 Sep;121(18):3252-3260. Pubmedid: 26038193. Pmcid: PMC4904725.
  • Kumar NB, Pow-Sang J, Egan KM, Spiess PE, Dickinson S, Salup R, Helal M, McLarty JW, Williams CR, Schreiber F, Parnes HL, Sebti S, Kazi A, Kang L, Quinn GP, Smith T, Yue B, Diaz K, Chornokur G, Crocker T, Schell MJ. Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention. Cancer Prev Res (Phila). 2015 Oct;8(10):879-887. Pubmedid: 25873370. Pmcid: PMC4596745.
  • Kim R, Schell MJ, Teer JK, Greenawalt DM, Yang M, Yeatman TJ. Co-evolution of somatic variation in primary and metastatic colorectal cancer may expand biopsy indications in the molecular era. PLoS One. 2015 May;10(5):e0126670. Pubmedid: 25974029. Pmcid: PMC4431733.
  • Chellappan SP, Pillai S, Trevino JG, Rawal B, Singh S, Kovacs M, Li X, Schell MJ, Haura EB, Bepler G. β-arrestin-1 mediates nicotine-induced metastasis through E2F1 target genes that modulate epithelial-mesenchymal transition. Cancer Res. 2015 Mar;75(6):1009-1020. Pubmedid: 25600647. Pmcid: PMC4359962.
  • Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh LF, Eysmans C, Richards A, Schell MJ, Fisher K, Horak CE, Inzunza HD, Yu B, Martinez AJ, Younos IH, Weber J. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res. 2015 Feb;21(4):712-720. Pubmedid: 25524312. Pmcid: PMC4620684.
  • Cives M, Kunz P, Morse B, Schell MJ, Campos T, Nguyen PT, Nandoskar P, Khandelwal V, Strosberg J. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocr Relat Cancer. 2015 Feb;22(1):1-9. Pubmedid: 25376618. Pmcid: PMC4643672.
  • Kothari N, Kim R, Jorissen RN, Desai J, Tie J, Wong HL, Farragher I, Jones I, Day FL, Li S, Sakthinandeswaren A, Palmieri M, Lipton L, Schell M, Teer JK, Shibata D, Yeatman T, Sieber OM, Gibbs P, Tran B. Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. Acta Oncol. 2015 Apr;54(4):487-492. Pubmedid: 25549537. Pmcid: PMC4743650.
  • Gilbert J, Schell MJ, Zhao X, Murphy B, Tanvetyanon T, Leon ME, Neil Hayes D, Haigentz M, Saba N, Nieva J, Bishop J, Sidransky D, Ravi R, Bedi A, Chung CH. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncol. 2015 Apr;51(4):376-382. Pubmedid: 25593015. Pmcid: PMC4459134.
  • Mahipal A, Denson AC, Djulbegovic B, Lush R, Kumar A, Juan TH, Schell MJ, Sullivan DM. Effect of Age on Clinical Outcomes in Phase 1 Trial Participants. Cancer Control. 2015 Apr;22(2):235-241. Pubmedid: 26068771.
  • Kumar NB, Quinn GP, Alexandrow MG, Gray J, Schell M, Sutton S, Haura EB. Chemoprevention Trial Feasibility Using Botanicals in Exceptionally High Risk Populations for Lung Cancer. J Clin Trials. 2014 Sep;4(4). Pubmedid: 26101725. Pmcid: PMC4474484.
  • Kothari N, Schell MJ, Teer JK, Yeatman T, Shibata D, Kim R. Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing. J Clin Pathol. 2014 Sep;67(9):764-767. Pubmedid: 25004944. Pmcid: PMC4743643.
  • Reich RR, Lengacher CA, Kip KE, Shivers SC, Schell MJ, Shelton MM, Widen RH, Newton C, Barta MK, Paterson CL, Farias JR, Cox CE, Klein TW. Baseline immune biomarkers as predictors of MBSR(BC) treatment success in off-treatment breast cancer patients. Biol Res Nurs. 2014 Oct;16(4):429-437. Pubmedid: 24477514. Pmcid: PMC4604564.
  • Lengacher CA, Reich RR, Kip KE, Barta M, Ramesar S, Paterson CL, Moscoso MS, Carranza I, Budhrani PH, Kim SJ, Park HY, Jacobsen PB, Schell MJ, Jim HS, Post-White J, Farias JR, Park JY. Influence of mindfulness-based stress reduction (MBSR) on telomerase activity in women with breast cancer (BC). Biol Res Nurs. 2014 Oct;16(4):438-447. Pubmedid: 24486564. Pmcid: PMC4559344.
  • Gray J, Haura EB, Chiappori A, Tanvetyanon T, Williams CC, Pinder-Schenk M, Kish JA, Kreahling JM, Lush RM, Neuger AM, Tetteh LF, Akar A, Zhao X, Schell MJ, Bepler G, Altiok S. A phase I, pharmacokinetic, and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. Clin Cancer Res. 2014 Mar;20(6):1644-1655. Pubmedid: 24429877. Pmcid: PMC4051132.
  • Han G, Schell MJ, Kim J. Improved survival modeling in cancer research using a reduced piecewise exponential approach. Stat Med. 2014 Jan;33(1):59-73. Pubmedid: 23900779. Pmcid: PMC3913785.
  • Rao NG, Trotti A, Kim J, Schell MJ, Zhao X, Amdur RJ, Brizel DM, Chambers MS, Caudell JJ, Miyamoto C, Rosenthal DI. Phase II multicenter trial of Caphosol for the reduction of mucositis in patients receiving radiation therapy for head and neck cancer. Oral Oncol. 2014 Aug;50(8):765-769. Pubmedid: 24954065. Pmcid: PMC4593395.
  • Creelan BC, Antonia S, Noyes D, Hunter TB, Simon GR, Bepler G, Williams CC, Tanvetyanon T, Haura EB, Schell MJ, Chiappori A. Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma. J Immunother. 2013 Oct;36(8):442-450. Pubmedid: 23994887. Pmcid: PMC3846277.
  • Etzkorn JR, Parikh RP, Marzban SS, Law K, Davis AH, Rawal B, Schell MJ, Sondak VK, Messina JL, Rendina LE, Zager JS, Lien MH. Identifying risk factors using a skin cancer screening program. Cancer Control. 2013 Oct;20(4):248-254. Pubmedid: 24077401. Pmcid: PMC4516026.
  • Li J, Bennett K, Stukalov A, Fang B, Zhang G, Yoshida T, Okamoto I, Kim JY, Song L, Bai Y, Qian X, Rawal B, Schell M, Grebien F, Winter G, Rix U, Eschrich S, Colinge J, Koomen J, Superti-Furga G, Haura EB. Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. Mol Syst Biol. 2013 Nov;9:705. Pubmedid: 24189400. Pmcid: PMC4039310.
  • Gray JE, Altiok S, Alexandrow MG, Walsh FW, Chen J, Schell MJ, Tai DF, Bepler G. Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers. Cancer. 2013 Mar;119(5):1023-1032. Pubmedid: 23065656. Pmcid: PMC3578040.
  • Pidala J, Kim J, Schell M, Lee SJ, Hillgruber R, Nye V, Ayala E, Alsina M, Betts B, Bookout R, Fernandez HF, Field T, Locke FL, Nishihori T, Ochoa JL, Perez L, Perkins J, Shapiro J, Tate C, Tomblyn M, Anasetti C. Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization. Bone Marrow Transplant. 2013 Mar;48(3):346-350. Pubmedid: 22863723. Pmcid: PMC4500122.
  • Messina JL, Fenstermacher DA, Eschrich S, Qu X, Berglund AE, Lloyd MC, Schell MJ, Sondak VK, Weber JS, Mulé JJ. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?. Sci Rep. 2013 Mar;2:765. Pubmedid: 23097687. Pmcid: PMC3479449.
  • Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, Chiappori A, Tanvetyanon T, Pinder-Schenck M, Gray J, Haura E, Antonia S, Fischer JR. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2013 Jul;31(19):2404-2412. Pubmedid: 23690416. Pmcid: PMC3691357.
  • Strosberg JR, Weber JM, Choi J, Campos TL, Valone TL, Han G, Schell MJ, Kvols LK. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol. 2012 Sep;23(9):2335-2341. Pubmedid: 22317769. Pmcid: PMC4559904.
  • Han G, Schell MJ, Kim J. Comparing Two Exponential Distributions Using the Exact Likelihood Ratio Test. Stat Biopharm Res. 2012 Oct;4(4):348-356. Pubmedid: 23814641. Pmcid: PMC3693095.
  • Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E, Antonia S, Bepler G. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis. Cancer. 2012 May;118(9):2525-2531. Pubmedid: 22028294. Pmcid: PMC3270127.
  • Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, Almhanna K, Kim R, Valone T, Jump H, Sullivan D. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer. 2012 May;48(7):997-1003. Pubmedid: 22445247. Pmcid: PMC4522922.
  • Kumar N, Crocker T, Smith T, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Slaton J, Anderson JK. Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer. Contemp Clin Trials. 2012 Mar;33(2):279-285. Pubmedid: 22101219. Pmcid: PMC3268882.
  • Kumar N, Crocker T, Smith T, Connors S, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, McLarty J, Fazili T, Williams CR, Schreiber F, Anderson K. Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures. J Clin Trials. 2012 Jan;2(1). Pubmedid: 24533253. Pmcid: PMC3924733.
  • Knapp CF, Sayegh Z, Schell MJ, Rawal B, Ochoa T, Sondak VK, Messina JL. Expression of CXCR4, E-cadherin, Bcl-2, and survivin in Merkel cell carcinoma: an immunohistochemical study using a tissue microarray. Am J Dermatopathxxx. 2012 Aug;34(6):592-596. Pubmedid: 22814318. Pmcid: PMC4634647.
  • Mahmood ST, Agresta S, Vigil C, Zhao X, Han G, D'Amato G, Calitri CE, Dean M, Garrett C, Schell MJ, Antonia S, Chiappori A. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. Int J Cancer. 2011 Oct;129(8):1963-1969. Pubmedid: 21154746. Pmcid: PMC3776586.
  • Djulbegovic B, Kumar A, Magazin A, Schroen AT, Soares H, Hozo I, Clarke M, Sargent D, Schell MJ. Optimism bias leads to inconclusive results-an empirical study. J Clin Epidemiol. 2011 Jun;64(6):583-593. Pubmedid: 21163620. Pmcid: PMC3079810.
  • Pillai S, Rizwani W, Li X, Rawal B, Nair S, Schell MJ, Bepler G, Haura E, Coppola D, Chellappan S. ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling. Mol Cell Biol. 2011 Jul;31(14):3052-3067. Pubmedid: 21606196. Pmcid: PMC3133413.
  • Bepler G, Olaussen KA, Vataire AL, Soria JC, Zheng Z, Dunant A, Pignon JP, Schell MJ, Fouret P, Pirker R, Filipits M, Brambilla E. ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am J Pathol. 2011 Jan;178(1):69-78. Pubmedid: 21224045. Pmcid: PMC3069904.
  • Turaga KK, Malafa MP, Jacobsen PB, Schell MJ, Sarr MG. Suicide in patients with pancreatic cancer. Cancer. 2011 Feb;117(3):642-647. Pubmedid: 20824626. Pmcid: PMC4704452.
  • Barlogie B, Bolejack V, Schell M, Crowley J. Prognostic factor analyses of myeloma survival with intergroup trial S9321 (INT 0141): examining whether different variables govern different time segments of survival. Ann Hematol. 2011 Apr;90(4):423-428. Pubmedid: 21153898. Pmcid: PMC3053415.
  • Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol. 2010 Mar;28(8):1387-1394. Pubmedid: 20142592. Pmcid: PMC3040065.
  • Chen JJ, Roberson PK, Schell MJ. The false discovery rate: a key concept in large-scale genetic studies. Cancer Control. 2010 Jan;17(1):58-62. Pubmedid: 20010520.
  • Metro G, Zheng Z, Fabi A, Schell M, Antoniani B, Mottolese M, Monteiro AN, Vici P, Lara Rivera S, Boulware D, Cognetti F, Bepler G. In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy. Cancer Invest. 2010 Feb;28(2):172-180. Pubmedid: 19968494. Pmcid: PMC3565222.
  • Chiappori AA, Zheng Z, Chen T, Rawal B, Schell MJ, Mullaney BP, Bepler G. Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer. J Thorac Oncol. 2010 Apr;5(4):484-490. Pubmedid: 20107425. Pmcid: PMC2861290.
  • Gergis U, Markey K, Greene J, Kharfan-Dabaja M, Field T, Wetzstein G, Schell MJ, Huang Y, Anasetti C, Perkins J. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. Bone Marrow Transplant. 2010 Apr;45(4):662-667. Pubmedid: 19684623. Pmcid: PMC2850960.
  • Gao J, Zheng Z, Rawal B, Schell MJ, Bepler G, Haura EB. Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells. Cancer Biol Ther. 2009 Sep;8(17):1671-1679. Pubmedid: 19633423. Pmcid: PMC3839311.
  • Lee JH, Schell MJ, Roetzheim R. Analysis of group randomized trials with multiple binary endpoints and small number of groups. PLoS One. 2009 Oct;4(10):e7265. Pubmedid: 19844579. Pmcid: PMC2760209.
  • Guo JP, Shu SK, He L, Lee YC, Kruk PA, Grenman S, Nicosia SV, Mor G, Schell MJ, Coppola D, Cheng JQ. Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer. Am J Pathol. 2009 Jul;175(1):324-333. Pubmedid: 19497997. Pmcid: PMC2708818.
  • Barami K, Sloan AE, Rojiani A, Schell MJ, Staller A, Brem S. Relationship of gliomas to the ventricular walls. J Clin Neurosci. 2009 Feb;16(2):195-202. Pubmedid: 19097905.
  • Reynolds C, Obasaju C, Schell MJ, Li X, Zheng Z, Boulware D, Caton JR, Demarco LC, O'Rourke MA, Shaw Wright G, Boehm KA, Asmar L, Bromund J, Peng G, Monberg MJ, Bepler G. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol. 2009 Dec;27(34):5808-5815. Pubmedid: 19884554. Pmcid: PMC2793001.
  • Lee J-H, Miladinovic B, Schell MJ. Statistical tutorial notes: analysis of two group comparisons, a practical guide. Med Probl Perform Art. 2009 Dec;166-169.
  • Simon GR, Extermann M, Chiappori A, Williams CC, Begum M, Kapoor R, Haura EB, Ismail-Khan R, Schell MJ, Antonia SJ, Bepler G. Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older. Cancer. 2008 May;112(9):2021-2029. Pubmedid: 18300255.
  • Tanvetyanon T, Robinson L, Schell M, Strong V, Kapoor R, Coit D, BeplerG. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrena metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol. 2008 Mar;26(7):1142-1147. Pubmedid: 18309950.
  • Zheng Z, Li X, Schell M, Chen T, Boulware D, Robinson L, Sommers E, Bepler G. Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer. 2008 Jun;112(12):2765-2773. Pubmedid: 18442042. Pmcid: PMC3857609.
  • Hozo I, Schell M, Djulbegovic B. Decision-making when data and inferences are not conclusive: risk-benefit and acceptable regret approach. Semin Hematol. 2008 Jul;45(3):150-159. Pubmedid: 18582621.
  • Chen DT, Schell MJ, Chen JJ, Fulp WJ, Eschrich S, Yeatman T. A predictive risk probability approach for microarray data with survival as an endpoint. J Biopharm Stat. 2008;18(5):841-852. Pubmedid: 18781520. Pmcid: PMC2717790.
  • Pavic D, Schell M, Dancel R, Sultana S, Lin L, Sejpal S, Pisano E. Comparison of three methods to increase knowledge about breast cancer and breast cancer screening in screening mammography patients. Acad Radiol. 2007 May;14(5):553-560. Pubmedid: 17434069.
  • Lloyd-Burton SM, Yu JC, Irvine RF, Schell MJ. Regulation of inositol 1,4,5-trisphosphate 3-kinases by calcium and localization in cells. J Biol Chem. 2007 Mar;282(13):9526-9535. Pubmedid: 17284449.
  • Schell M, Yankaskas B, Ballard-Barbash R, Qaqish B, Barlow W, RosenbergRD, Smith-Bindman R. Evidence-based target recall rates for screening mammography. Radiology. 2007 Jun;243(3):681-689. Pubmedid: 17517927.
  • Graham DK, Salzberg DB, Kurtzberg J, Sather S, Matsushima GK, Keating AK, Liang X, Lovell MA, Williams SA, Dawson TL, Schell MJ, Anwar AA, Snodgrass HR, Earp HS. Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin Cancer Res. 2006 May;12(9):2662-2669. Pubmedid: 16675557.
  • Stinchcombe T, Choi J, Schell M, Mears A, Jones P, Nachtsheim R, Socinski M. Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status. Lung Cancer. 2006 Feb;51(2):237-243. Pubmedid: 16378657.
  • Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS, Sullivan DM. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood. 2006 Dec;108(12):3881-3889. Pubmedid: 16917002. Pmcid: PMC1895461.
  • Kondo S, Wakisaka N, Schell MJ, Horikawa T, Sheen TS, Sato H, Furukawa M, Pagano JS, Yoshizaki T. Epstein-Barr virus latent membrane protein 1 induces the matrix metalloproteinase-1 promoter via an Ets binding site formed by a single nucleotide polymorphism: enhanced susceptibility to nasopharyngeal carcinoma. Int J Cancer. 2005 Jun;115(3):368-376. Pubmedid: 15688379.
  • Ivanova A, Qaqish B, Schell M. Continuous toxicity monitoring in phase II trials in oncology. Biometrics. 2005 Jun;61(2):540-545. Pubmedid: 16011702.
  • Titus MA, Gregory CW, Ford OH , Schell MJ, Maygarden SJ, Mohler JL. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res. 2005 Jun;11(12):4365-4371. Pubmedid: 15958619.
  • Lindley C, Goodin S, McCune J, Kane M, Amamoo MA, Shord S, Pham T, Yowell S, Laliberte K, Schell M, Bernard S, Socinski MA. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. Am J Clin Oncol. 2005 Jun;28(3):270-276. Pubmedid: 15923800.
  • Titus M, Schell M, Lih F, Tomer K, Mohler J. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res. 2005 Jul;11(13):4653-4657. Pubmedid: 16000557.
  • Hensing T, Schell M, Lee J, Socinski M. Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. Lung Cancer. 2005 Feb;47(2):253-259. Pubmedid: 15639724.
  • Mohler J, Gaston K, Moore D, Schell M, Cohen B, Weaver C, Petrusz P. Racial differences in prostate androgen levels in men with clinically localized prostate cancer. J Urol. 2004 Jun;171(6 Pt 1):2277-2280. Pubmedid: 15126802.
  • Yankaskas B, Schell M, Miglioretti D. Recall and detection rates in screening mammography. Cancer. 2004;101(11):2710-2712. Pubmedid: 15499596.
  • Hensing T, Peterman A, Schell M, Lee J, Socinski M. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer. 2003 Aug;98(4):779-788. Pubmedid: 12910523.
  • Socinski MA, Neubauer MA, Olivares J, Ketchel S, Tynan M, Moore M, Lee JH, Davis K, Schell M, Garfield D. Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer. Lung Cancer. 2003 Apr;40(1):91-97. Pubmedid: 12660013.
  • Abrahamson P, Dunlap L, Amamoo M, Schell M, Braeuning M, Pisano E. Factors predicting successful needle-localized breast biopsy. Acad Radiol. 2003;10(6):601-606. Pubmedid: 12809412.
  • Socinski M, Schell M, Bakri K, Peterman A, Lee J, et al.. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel. Cancer. 2002 Sep;95(6):1265-1273. Pubmedid: 12216094.
  • McHale M, Berman M, Keefe K, Schell M, Peng Y, Monk B. Influence of Serum and Tissue Micronutrient Levels on the Regression of Untreated Cervical Intraepithelial Neoplasia 2 and 3. J Low Genit Tract Dis. 2002 Oct;6(4):220-224. Pubmedid: 17051026.
  • Bloedon LT, Jeffcoat AR, Lopaczynski W, Schell MJ, Black TM, Dix KJ, Thomas BF, Albright C, Busby MG, Crowell JA, Zeisel SH. Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women. Am J Clin Nutr. 2002 Nov;76(5):1126-1137. Pubmedid: 12399289.
  • Socikski M, Schell M, Peterman A, Bakri K, Yates S, Gitten R, Unger P, Lee J, Lee J, et al.. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2002 Mar;20(5):1335-1343. Pubmedid: 11870177.
  • Kidd JF, Pilkington MF, Schell MJ, Fogarty KE, Skepper JN, Taylor CW, Thorn P. Paclitaxel affects cytosolic calcium signals by opening the mitochondrial permeability transition pore. J Biol Chem. 2002 Feb;277(8):6504-6510. Pubmedid: 11724773.
  • Socinski MA, Rosenman JG, Halle J, Schell MJ, Lin Y, Russo S, Rivera MP, Clark J, Limentani S, Fraser R, Mitchell W, Detterbeck FC. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial. Cancer. 2001 Sep;92(5):1213-1223. Pubmedid: 11571735.
  • Yankaskas BC, Schell MJ, Bird RE, Desrochers DA. Reassessment of breast cancers missed during routine screening mammography: a community-based study. Ajr Am J Roentgenol. 2001 Sep;177(3):535-541. Pubmedid: 11517043.
  • Yankaskas BC, Cleveland RJ, Schell MJ, Kozar R. Association of recall rates with sensitivity and positive predictive values of screening mammography. Ajr Am J Roentgenol. 2001 Sep;177(3):543-549. Pubmedid: 11517044.
  • Keefe KA, Schell MJ, Brewer C, McHale M, Brewster W, Chapman JA, Rose GS, McMeeken DS, Lagerberg W, Peng YM, Wilczynski SP, Anton-Culver H, Meyskens FL, Berman ML. A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1029-1035. Pubmedid: 11588128.
  • Charles MJ, Schell MJ, Willman E, Gross HB, Lin Y, Sonnenberg S, Graham ML. Organochlorines and 8-hydroxy-2'-deoxyguanosine (8-OHdG) in cancerous and noncancerous breast tissue: do the data support the hypothesis that oxidative DNA damage caused by organochlorines affects breast cancer?. Arch Environ Contam Toxicol. 2001 Oct;41(3):386-395. Pubmedid: 11503078.
  • O'Malley MS, Earp JA, Hawley ST, Schell MJ, Mathews HF, Mitchell J. The association of race/ethnicity, socioeconomic status, and physician recommendation for mammography: who gets the message about breast cancer screening?. Am J Public Health. 2001 Jan;91(1):49-54. Pubmedid: 11189825. Pmcid: PMC1446507.
  • Poole ME, Sailer SL, Rosenman JG, Tepper JE, Weissler MC, Shockley WW, Yarbrough WG, Pillsbury HC, Schell MJ, Bernard SA. Chemoradiation for locally advanced squamous cell carcinoma of the head and neck for organ preservation and palliation. Arch Otolaryngol Head Neck Surg. 2001 Dec;127(12):1446-1450. Pubmedid: 11735812.
  • Duell EJ, Millikan RC, Savitz DA, Schell MJ, Newman B, Tse CJ, Sandler DP. Reproducibility of reported farming activities and pesticide use among breast cancer cases and controls. A comparison of two modes of data collection. Ann Epidemiol. 2001 Apr;11(3):178-185. Pubmedid: 11248581.
  • Braeuning MP, Earp JL, O'Brien SM, Schell MJ, Denham AC, Pisano ED, O'Malley MS. Informing patients of diagnostic mammography results: mammographer's opinions. Acad Radiol. 2000 May;7(5):335-340. Pubmedid: 10803613.
  • Stark A, Hulka BS, Joens S, Novotny D, Thor AD, Wold LE, Schell MJ, Melton LJ, Liu ET, Conway K. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol. 2000 Jan;18(2):267-274. Pubmedid: 10637239.
  • Huang WY, Newman B, Millikan RC, Conway K, Hulka BS, Schell MJ, Liu ET. Risk of breast cancer according to the status of HER-2/neu oncogene amplification. Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):65-71. Pubmedid: 10667465.
  • Socinski MA, Rosenman JG, Schell MJ, Halle J, Russo S, Rivera MP, Clark J, Limentani S, Fraser R, Mitchell W, Detterbeck FC. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I trial. Cancer. 2000 Aug;89(3):534-542. Pubmedid: 10931452.
  • Osann KE, Lowery JT, Schell MJ. Small cell lung cancer in women: risk associated with smoking, prior respiratory disease, and occupation. Lung Cancer. 2000 Apr;28(1):1-10. Pubmedid: 10704703.
  • Koizumi S, Bootman MD, Bobanović LK, Schell MJ, Berridge MJ, Lipp P. Characterization of elementary Ca2+ release signals in NGF-differentiated PC12 cells and hippocampal neurons. Neuron. 1999 Jan;22(1):125-137. Pubmedid: 10027295.
  • Braeuning MP, Cooper HW, O'Brien S, Burns CB, Washburn DB, Schell MJ, Pisano ED. Effects of processing conditions on mammographic image quality. Acad Radiol. 1999 Aug;6(8):464-470. Pubmedid: 10480042.
  • Cooper DM, Schell MJ, Thorn P, Irvine RF. Regulation of adenylyl cyclase by membrane potential. J Biol Chem. 1998 Oct;273(42):27703-27707. Pubmedid: 9765307.
  • Eliasson MJ, Blackshaw S, Schell MJ, Snyder SH. Neuronal nitric oxide synthase alternatively spliced forms: prominent functional localizations in the brain. Proc Natl Acad Sci U S A. 1997 Apr;94(7):3396-3401. Pubmedid: 9096405. Pmcid: PMC20381.
  • Atiba JO, Manzardo AM, Thiruvengadam R, Schell MJ, Meyskens FL. Restoration of oral all-trans retinoic acid bioavailability after a brief drug holiday. Am J Ther. 1997 Apr;4(4):134-140. Pubmedid: 10423603.
  • Manetta A, Schubbert T, Chapman J, Schell MJ, Peng YM, Liao SY, Meyskens FJ. beta-Carotene treatment of cervical intraepithelial neoplasia: a phase II study. Cancer Epidemiol Biomarkers Prev. 1996 Nov;5(11):929-932. Pubmedid: 8922303.
  • Wilder-Smith P, Arrastia AM, Schell MJ, Liaw LH, Grill G, Berns MW. Effect of ND:YAG laser irradiation and root planing on the root surface: structural and thermal effects. J Periodontol. 1995 Dec;66(12):1032-1039. Pubmedid: 8683415.
  • Schell MJ, Molliver ME, Snyder SH. D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release. Proc Natl Acad Sci U S A. 1995 Apr;92(9):3948-3952. Pubmedid: 7732010. Pmcid: PMC42079.
  • Dinerman JL, Dawson TM, Schell MJ, Snowman A, Snyder SH. Endothelial nitric oxide synthase localized to hippocampal pyramidal cells: implications for synaptic plasticity. Proc Natl Acad Sci U S A. 1994 May;91(10):4214-4218. Pubmedid: 7514300. Pmcid: PMC43755.
  • Santana VM, Schell MJ, Williams R, Bowman LC, Thompson EI, Brenner MK, Mirro J. Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors. Bone Marrow Transplant. 1992 Nov;10(5):457-462. Pubmedid: 1464010.
  • Santana VM, Mirro J, Kearns C, Schell MJ, Crom W, Blakley RL. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol. 1992 Mar;10(3):364-370. Pubmedid: 1346800.
  • Angel CA, Pratt CB, Rao BN, Schell MJ, Parham DM, Lobe TE, Fleming ID. Carcinoembryonic antigen and carbohydrate 19-9 antigen as markers for colorectal carcinoma in children and adolescents. Cancer. 1992 Mar;69(6):1487-1491. Pubmedid: 1311626.
  • Stute N, Santana VM, Rodman JH, Schell MJ, Ihle JN, Evans WE. Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood. 1992 Jun;79(11):2849-2854. Pubmedid: 1375115.
  • Schell MJ, Ochs JJ, Schriock EA, Carter M. A method of predicting adult height and obesity in long-term survivors of childhood acute lymphoblastic leukemia. J Clin Oncol. 1992 Jan;10(1):128-133. Pubmedid: 1727914.
  • Relling MV, Cherrie J, Schell MJ, Petros WP, Meyer WH, Evans WE. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther. 1991 Sep;50(3):308-313. Pubmedid: 1680593.
  • Schriock EA, Schell MJ, Carter M, Hustu O, Ochs JJ. Abnormal growth patterns and adult short stature in 115 long-term survivors of childhood leukemia. J Clin Oncol. 1991 Mar;9(3):400-405. Pubmedid: 1999710.
  • Wang WC, Kovnar EH, Tonkin IL, Mulhern RK, Langston JW, Day SW, Schell MJ, Wilimas JA. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr. 1991 Mar;118(3):377-382. Pubmedid: 1999776.
  • Evans WE, Schell MJ, Pui CH. MTX clearance is more important for intermediate-risk ALL. J Clin Oncol. 1990 Jun;8(6):1115-1116. Pubmedid: 2348226.
  • Kalwinsky DK, Raimondi SC, Schell MJ, Mirro J, Santana VM, Behm F, Dahl GV, Williams D. Prognostic importance of cytogenetic subgroups in de novo pediatric acute nonlymphocytic leukemia. J Clin Oncol. 1990 Jan;8(1):75-83. Pubmedid: 2295913.
  • Ribeiro RC, Sandrini Neto RS, Schell MJ, Lacerda L, Sambaio GA, Cat I. Adrenocortical carcinoma in children: a study of 40 cases. J Clin Oncol. 1990 Jan;8(1):67-74. Pubmedid: 2295912.
  • Hutchinson RE, Kunkel KD, Schell MJ, Jackson CW, Nelson EJ, Wang WC, Fischl SJ, Taylor LB, Garcez RB, Pui CH. Beneficial effect of brief pre-transfusion incubation of platelets at 37 degrees C. Lancet. 1989 May;1(8645):986-988. Pubmedid: 2565517.
  • Schell MJ, McHaney VA, Green AA, Kun LE, Hayes FA, Horowitz M, Meyer WH. Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation. J Clin Oncol. 1989 Jun;7(6):754-760. Pubmedid: 2715805.
  • Carter M, Kalwinsky DK, Dahl GV, Santana VM, Mason CA, Schell MJ. Childhood acute promyelocytic leukemia: a rare variant of nonlymphoid leukemia with distinctive clinical and biologic features. Leukemia. 1989 Apr;3(4):298-302. Pubmedid: 2927178.
  • Pui CH, Kalwinsky DK, Schell MJ, Mason CA, Mirro J, Dahl GV. Acute nonlymphoblastic leukemia in infants: clinical presentation and outcome. J Clin Oncol. 1988 Jun;6(6):1008-1013. Pubmedid: 3373258.
  • Parkinson JF, Akard LP, Schell MJ, Gabig TG. Cell-free activation of phagocyte NADPH-oxidase: tissue and differentiation-specific expression of cytosolic cofactor activity. Biochem Bioph Res Co. 1987 Jun;145(3):1198-1204. Pubmedid: 3038092.
  • Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1987 Jun;316(26):1627-1632. Pubmedid: 3495732.
  • Gabig TG, English D, Akard LP, Schell MJ. Regulation of neutrophil NADPH oxidase activation in a cell-free system by guanine nucleotides and fluoride. Evidence for participation of a pertussis and cholera toxin-insensitive G protein. J Biol Chem. 1987 Feb;262(4):1685-1690. Pubmedid: 3027097.